The phase III Continuous or Intermittent (COIN) trial failed to show a benefit in overall survival (OS) of cetuximab in combination with chemotherapy for patients with metastatic colorectal cancer. High derived neutrophil to lymphocyte ratio (dNLR) has been shown to be prognostic in patients with metastatic colorectal cancer. The aim of this analysis is to evaluate dNLR as a predictive biomarker of the survival according to RAS and BRAF mutations status within the COIN trial. A post-hoc exploratory analysis of the COIN trial arms A and B was carried out. All patients with available white blood cell and neutrophil data were analysed. The dNLR was calculated using a formula that has previously shown predictive power in cancer patients: dNLR = ANC/(WBC − ANC). A high dNLR was defined as a value of 2.2 or more. dNLR was correlated with clinical outcomes using Kaplan-Meier and Cox regression analysis. A total of 1603 patients were assigned to the oxaliplatinbased chemotherapy (arm A, N = 815) or oxaliplatin-based chemotherapy plus cetuximab (arm B, N = 815) arms. There was a strong association between dNLR level and overall survival (OS) using Kaplan-Meier analysis. In all mutation groups, dNLR less than 2.2 was associated with better OS compared to dNLR of 2.2 or more. The median OS in patients with wild-type disease (dNLR < 2.2 vs. dNLR ≥ 2.2) was 22.8 versus 13.1 months [hazard ratio (HR) = 1.33]; 16.9 versus 11.8 months (HR = 1.36) in patients with RAS mutant tumours; and 12.6 versus 6.8 months (HR = 1.67) in patients with BRAF mutant tumours. In patients with dNLR less than 2.2, the median OS was 19.2 months in arm A compared to 18.0 months in arm B (HR = 1.11). Among patients with dNLR greater than or equal to 2.2, the median OS was 13.0 months in arm A compared with 13.1 months in arm B (HR = 0.96). dNLR is strongly prognostic for survival in all mutation groups. dNLR does not predict for benefit from the addition of cetuximab. Anti-Cancer Drugs 28:546-550
Background
The Continuous or Intermittent (COIN) phase III randomized study showed a prognostic effect of BRAF, KRAS and NRAS mutations on the outcome of patients with advanced colorectal cancer (CRC). However, the benefit of additional cetuximab treatment to oxaliplatinbased chemotherapy in the first-line treatment of these patients was not proved [1] . Comparable studies have shown mixed response outcome data for patients with RAS wild-type tumours in the context of chemotherapy combinations with epidermal growth factor receptor (EGFR) inhibitors [2] [3] [4] [5] . To further clarify subgroup sensitivity to EGFR inhibition, prospective testing is needed [6, 7] .
The tumour microenvironment and the inflammatory response have been shown to play a vital role in cancer development. Measurable serum parameters of C-reactive protein, neutrophil/lymphocyte ratio (NLR) and the platelet-lymphocyte ratio have been associated with poor outcomes in patients with CRC [8] [9] [10] . NLR is a marker of host inflammation and may reflect cytokine activation and therefore be a surrogate marker of more aggressive disease. A recently reported meta-analysis of 100 studies comprising 40 559 patients with various solid tumours found that a NLR of more than 4 was associated with poorer overall survival (OS) [hazard ratio (HR) = 1.81; 95% confidence interval (CI): 1.67-1.97; P < 0.001]. This effect was observed in all of the disease sites, subgroups and stages [11] . Within this meta-analysis, including six prospective studies, a total of 1817 patients with metastatic colorectal cancer (mCRC) were included.
The COIN trial did not collect lymphocyte count data; however, the derived neutrophil to lymphocyte ratio (dNLR) has been shown to have similar prognostic value [12] . In a previous analysis of the COIN trial, we determined that dNLR is predictive of survival when administering intermittent versus continuous treatment [13] . In this study, we examined dNLR as a prognostic factor and assessed its predictive power in terms of the potential benefit of EGFR inhibition, particularly in the RAS and BRAF populations.
Methods
The phase III COIN trial was conducted by the Medical Research Council Clinical Trials Unit and was overseen by an independent trial steering committee. The trial was approved by national research ethics committees in the UK and Ireland and both the Medicines and Healthcare Regulatory Agency and Irish Medicines Board. The trial design and eligibility criteria have been reported previously [1] .
The primary objective of the COIN trial was to assess the effect of the addition of EGFR-targeted monoclonal antibody (cetuximab) to continuous oxaliplatin and fluoropyrimidine combination chemotherapy on survival. Shortly after COIN completed recruitment, external evidence showed that anti-EGFR antibodies were unlikely to benefit mCRC patients whose tumours carry KRAS mutations [14] .
Treatment allocation was nonblinded and assigned randomly (1 : 1) to the control arm of continuous oxaliplatinbased (oxaliplatin plus capecitabine or oxaliplatin plus fluorouracil and folinic acid) chemotherapy (arm A) or continuous chemotherapy plus cetuximab (arm B). The treatment was continued until progression of disease, development of cumulative toxicities or patient choice [1] .
We have carried out a post-hoc exploratory analysis of the prognostic and predictive power of dNLR in the COIN trial arms A and B. All patients with available white blood cell (WBC) and neutrophil data were analysed. Unfortunately, lymphocyte data were not collected at patient entry to the COIN trial.
Derived neutrophil/lymphocyte ratio calculation WBC and absolute neutrophil count (ANC) were collected on all patients at enrolment into the COIN trial. dNLR was calculated using the following formula: dNLR = ANC/(WBC-ANC) [8, 12] .
Statistical methods
All statistical analyses were carried out by the Cancer Research UK and University College London Cancer Trials Centre. Stats, version 12.1 (release 12, 2011; StataCorp LP, College Station, Texas, USA) was used to analyse data.
A high dNLR was defined as greater than or equal to 2.2. dNLR was correlated with clinical outcomes including OS, progression-free survival (PFS) and objective response rate. Kaplan-Meier survival curves were generated based on dNLR. Comparison between groups was performed using Cox regression analysis adjusted for treatment, age, sex, tumour status (resected, unresected or local recurrence), primary site (colon, rectum, rectosigmoid junction, multiple growths), liver-only metastases (yes vs. no), number of metastatic sites (0, 1, 2, ≥ 3), platelets (< 400 000 vs. ≥ 400 000 µl) and alkaline phosphatase (< 300 vs. ≥ 300 U/l). Prognostic value was assessed with receiver operating characteristic analysis, using 1-year survival as the outcome, and reporting the estimate of area under the curve [13] .
Results
Overall, 1630 of 2445 patients in the COIN trial were randomized to arm A (chemotherapy) and arm B (chemotherapy + cetuximab). Our total cohort included 1603 patients (accounting for 98.3% of the total study population), excluding nine patients with no WBC and ANC data and 18 patients with other missing data. The median value of dNLR was 2.2; the baseline characteristics in each dNLR group are shown in Table 1 . Copyright r 2017 Wolters Kluwer Health, Inc. All rights reserved.
Derived neutrophil/lymphocyte ratio as a prognostic marker
There was a strong association between dNLR level and outcome. We found that patients with dNLR greater than or equal to 2.2 had a HR of 1.35 (95% CI: 1.20-1.52; P < 0.001) for OS ( Fig. 1 ) and 1.25 (95% CI: 1.13-1.40; P < 0.001) for PFS.
In patients with dNLR less than 2.2, the median OS was 19.2 months in arm A and 18.0 months in arm B -HR = 1.11 (Fig. 2a) . Among patients with dNLR greater than or equal to 2.2, the median OS was 13.0 months in arm A compared to 13.1 months in arm B -HR = 0.96 (Fig. 2b) . A differential treatment effect between the two dNLR groups was not observed (P = 0.21).
The area under the curve for dNLR was 63.9% (95% CI: 61.1-66.7). Dichotomizing the data at the median value of dNLR (2.2) resulted in a true detection rate of 57.7% and a false-positive rate of 38.5% for 1-year survival.
RAS/RAF mutations
RAS and BRAF mutation status was available for 1263 (78.8%) patients. Of these, 575 (45.1%) were RAS/RAF wild type; 587 (46.5%) were RAS mutated; and 101 (8.0%) were BRAF mutated. There was clear evidence of an association between low dNLR and improved OS in each of these four groups (Table 2) . No evidence for a beneficial effect of additional cetuximab was found in any group of patients.
Discussion
Inflammation is well reported to contribute towards tumour formation and is now a recognized hallmark of cancer. It is known that the tumour microenvironment can attract, educate and control invading leucocytes to promote angiogenesis, viability, motility and invasion [15] . The stroma around solid cancers has been compared with a poorly healing wound and it is associated chronic inflammation [16] . The association of high NLR with worse survival is more pronounced in metastatic than localized disease and therefore may reflect greater tumour burden or a more prolonged chronic inflammatory process [11] . It is uncertain why NLR is more strongly associated with outcome than neutrophil or lymphocyte counts alone. This biological mechanism requires further investigation. Neutrophils may act as tumour-promoting leucocytes through transforming growth factor-β, interleukin-10 and regulatory T-cells-induced signal pathways and circulating neutrophils can also secrete the vascular endothelial growth factor, resulting in higher levels of vascular endothelial growth factor in the tumours [17] . High NLR may also represent a relatively depleted lymphocyte count, potentially impairing the host immune response to malignancy and therefore negatively impact outcomes.
There is also evidence that RAS mutations influence the host immune response. KRAS and NRAS are critical components of intracellular signalling. Functional specificity of mutated RAS isoforms has been shown and the role of mutant proteins in onset and progression of disease continues to be investigated [18, 19] . NRAS activation has been shown to suppress stress-induced apoptosis in human CRC cells lines and therefore contribute towards CRC development. Mouse models also indicated that NRAS mutations enhance colon cancer development in the context of inflammation [19] .
Recently, a retrospective analysis investigated the relationship of NLR with molecular alterations (KRAS/ NRAS/BRAF/PIK3CA/CIMP) and circulating cytokines [20] . High NLR was associated with a poor prognosis in mCRC, independent of the common molecular alterations. Similarly, in our study, the correlation between dNLR and survival was observed in all mutation groups. These results were consequently not predictive of benefit from the addition of cetuximab in any particular mutation group. Although modest, our results have shown a numerically poorer survival for patients with dNLR greater than or equal to 2.2 treated with additional cetuximab compared with those treated with chemotherapy alone. The BRAF mutated cohort was relatively small in number and underpowered. These data should therefore be interpreted with caution as this limits the ability to differentiate between prognostic and predictive value of dNLR in the context of chemotherapy with cetuximab. A meta-analysis with similar BRAF mutated cohorts may be of value.
CRC patients with elevated NLR have been characterized by aggressive biology and a distinctive expression profile of cytokines involved in angiogenesis, inflammation and Kaplan-Meier curves for overall survival according to dNLR. CI, confidence interval; dNLR, derived neutrophil to lymphocyte ratio; HR, hazard ratio.
regulation of the epidermal growth factor axis. In the retrospective analysis, elevated NLR was more than 5 [20] . There is ongoing statistical uncertainty with respect to the cutoff of elevated NLR and the subsequent interpretation of NLR as a prognostic and predictive biomarker. Our analysis confirms the prognostic value of dNLR in advanced CRC. We have found a strong association between dNLR with OS and PFS. dNLR is therefore moderately prognostic for 1-year survival in the COIN trial. This was independent of the treatment allocation arm.
Conclusion
Our study gives further support for the use of dNLR as a readily available, inexpensive biomarker for the prediction of survival in mCRC. We have shown that in the randomized phase III COIN trial, dNLR was a reliable prognostic marker in patients with mCRC who received first-line oxaliplatin-based chemotherapy with or without additional cetuximab. dNLR was strongly prognostic for survival in all mutations groups, especially in patients with BRAF mutant tumours. dNLR was not predictive of benefit from cetuximab. Kaplan-Meier curves for overall survival according to treatment, in low (a) and high (b) dNLR. CI, confidence interval; dNLR, derived neutrophil to lymphocyte ratio; HR, hazard ratio. dNLR as a prognostic factor Wood et al. 549
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